Ristau BT, et al. - The target of this research was to contemplate the deliverables of multiparametric magnetic resonance imaging/ultrasound fusion prostate biopsy. The intention was to define novel and practical metrics. It was determined that Actionable Intelligence Metric (AIM) and Reduction Metric (ReM) served as novel, clinically relevant quantification metrics in order to standardize reporting of targeted prostate biopsy (TB) deliverables. Actionable information (AIM) was afforded bt TB in ∼25% of men. ReM assessment underscored the finding that transrectal ultrasound-guided prostate biopsy (TRUS-B) could be omitted only after cautiously regarding the risk of missing clinically significant cancers.